NORMAL SITUATION

Galapagos Biopharma Belgium

Export PDF

Company — Normal situation.

Financial year 2024 · Closed on 30/06/2024

Net result137,5 k €+1 405,4 %over 1 year
Revenue5,1 M €-61,4 %over 1 year
Equity1,3 M €+164,8 %over 1 year
Workforce14,2 ETP-2,7 %over 1 year

Identity

Source · BCE/KBO

Galapagos Biopharma Belgium is a company registered in Belgium. It employs on average 14,2 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0727.786.248
Legal form
Private limited company
Contributed capital
500 000,00 €
Latest accounts
30/06/2024
Average workforce
14,2 ETP
Joint committees (1)
  • 200
Signals
ProfitableSolid equityGood liquidityPositive cashflowPositive EBITDAHigh revenue

Financials

Source · NBB, 6 filings

Trend over 4 financial years

2024202120202019
Income statement
Revenue5,1 M €13,2 M €––
EBITDA216 k €289 k €––
Operating result216 k €263,7 k €––
Net result137,5 k €9,1 k €-22,8 k €-249,6 €
Balance sheet
Equity1,3 M €486,1 k €476,9 k €499,8 k €
Total assets4 M €15,6 M €2,8 M €887,6 k €
Cash723,9 k €2,2 M €1,3 M €468,6 k €
Debts2,7 M €15 M €2,3 M €387,9 k €
Other
Workforce14,2 ETP14,6 ETP9,3 ETP4,0 ETP

Board of directors

Source · NBB, accounts to 30/06/2024

3 active · 4 ended

Active mandates

Marcel de Jong

Director · since 31 janvier 2024

Active
Samara Orsatti

Director · since 31 janvier 2024

Active
Michele Manto

Director · since 09 décembre 2021

Active

Ended mandates

Bart Filius

Director

Ended
Michele Manto

Director

Ended
Onno van de Stolpe

Director

Ended
Xavier Maes

Director

Ended

Full financial information

Source · NBB
202420232022202120202019
Type of accountFull modelFull modelFull modelFull modelFull modelFull model
Start of the financial year01/01/202401/01/202301/01/202201/01/202101/01/202005/06/2019
Closing of the financial year30/06/202431/12/202331/12/202231/12/202131/12/202031/12/2019
Length of the financial year6 months12 months12 months12 months12 months7 months
Filing date08/10/202411/06/202409/06/202307/06/202227/05/202129/05/2020
General meeting30/09/202421/05/202416/05/202317/05/202218/05/202119/05/2020
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 6 filings
ModelClosingGeneral meetingFiledLanguageDocument
Full model30/06/202430/09/202408/10/2024DutchPDF
Full model31/12/202321/05/202411/06/2024DutchPDF
Full model31/12/202216/05/202309/06/2023DutchPDF
Full model31/12/202117/05/202207/06/2022DutchPDF
Full model31/12/202018/05/202127/05/2021DutchPDF
Full model31/12/201919/05/202029/05/2020DutchPDF

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 30/06/2024

3 active · 4 ended

Active mandates

Marcel de Jong

Director · since 31 janvier 2024

Active
Samara Orsatti

Director · since 31 janvier 2024

Active
Michele Manto

Director · since 09 décembre 2021

Active

Ended mandates

Bart Filius

Director

Ended
Michele Manto

Director

Ended
Onno van de Stolpe

Director

Ended
Xavier Maes

Director

Ended

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Dissolution17/10/2024
    RUBRIEK EINDE (STOPZETTING, INTREKKING STOPZETTING, NIETIGHEID, GER. AK., GERECHTELIJKE REORGANISATIE, ENZ... - RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
    PDF
  • Restructuring08/08/2024
    RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...) - DIVERSEN
    PDF
  • Mandates29/02/2024
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates01/08/2023
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates27/07/2022
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates08/04/2022
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates20/12/2021
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Other07/06/2019
    RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2024
    Annual accounts 2024137,5 k €↑
  2. 2021
    Annual accounts 20219,1 k €↑
  3. 2020
    Annual accounts 2020-22,8 k €↓
  4. 2019
    Annual accounts 2019-249,6 €